Semaglutide, also known by the brand names Ozempic, Rybelsus and Wegovy, is an FDA-approved once-weekly GLP-1 receptor agonist manufactured by Novo Nordisk
high doses may cause mild GI upset Monitor liver function if used long-term Common Side Effects Injection site reactions: pain, bruising, redness, swelling Mild nausea or stomach upset Headache Unusual taste in the mouth Mild fatigue after injection Temporary body odor changes (from high-dose choline) Seek Medical Attention For Signs of allergic reaction: rash, hives, swelling, difficulty breathing Severe injection site reaction or infection Unusual chest pain or heart palpitations References PT-141 / Bremelanotide (Compounded) PT-141, also known as bremelanotide, is a melanocortin receptor agonist that acts on the central nervous system to address hypoactive sexual desire disorder (HSDD)
But this week, they have approximately 1.5 mg of active medication in their body as a simplified illustration, not a precise pharmacokinetic calculation
Microdosing GLP-1 (glucagon-like peptide-1) agonist weight loss drugs involves taking smaller doses of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), or orforglipron (Foundayo) than recommended by the U.S
The most common compounded semaglutide concentrations are: 2 mg/mL 2.5 mg/mL 3 mg/mL 5 mg/mL At each of these concentrations, 50 units delivers a different milligram dose
